Physiopathological Treatment Approach and Position of Pioglitazone in Type 2 Diabetes
Authors:
- Abdulhalim ŞenyiğitAŞAbdulhalim Şenyiğit
- Mustafa KanatMKMustafa Kanat
Open Access
- 25 September 2017
- journal article
- Published by Anadolu Klinigi Tip Bilimleri Dergisi in Anadolu Kliniği Tıp Bilimleri Dergisi
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- 8. Pharmacologic Approaches to Glycemic TreatmentDiabetes Care, 2016
- Pioglitazone after Ischemic Stroke or Transient Ischemic AttackNew England Journal of Medicine, 2016
- Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013Diabetes Care, 2013
- Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 DiabetesDiabetes Care, 2013
- In Vivo Actions of Peroxisome Proliferator–Activated ReceptorsDiabetes Care, 2013
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 DiabetesJAMA, 2008
- Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 DiabetesJAMA, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- ThiazolidinedionesNew England Journal of Medicine, 2004